The FDA has cleared the Stimpod NMS460 (Xavant Technology), a non-invasive neuromodulation device for the symptomatic relief and management of chronic intractable pain. When applied to the affected area transcutaneously, the device’s proprietary hybrid pulsed radio frequency (PRF) waveform creates electromagnetic effects similar to invasive pulsed radio frequency treatments. It also incorporates nerve-locating technology, featuring a nerve-mapping probe that enables practitioners to locate nerves and evaluate the treatment progress of damaged nerves.
According to the company, case studies have shown instant and dramatic relief of chronic intractable pain with use of the Stimpod NMS460. Beyond chronic intractable pain, the device was also cleared as an adjunct in the management of post-surgical pain, acute pain problems, and pain control due to rehabilitation.Next Story